Trial · NCT03053115
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline SHBG serum levels at 12 and 24 weeks (nmol/L) |
| Secondary | BMI (kg/m2) | baseline and then repeated at 6, 12 weeks and 24 weeks | body mass index |
| Secondary | quality of life changes | baseline and then repeated at 12 weeks and 24 weeks | score at validated questionnaires |
| Secondary | change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline TSH serum levels at 12 and 24 weeks (microIU/ml) |
| Secondary | change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline free triiodothyronine (fT3) serum levels at 12 and 24 weeks (pmol/L) |
| Secondary | change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline free levothyroxine (fT4) serum levels at 12 and 24 weeks (pmol/L) |
| Secondary | change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline total cholesterol serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline HDL cholesterol serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline HDL cholesterol serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline triglycerides serum levels at 12 and 24 weeks (mg/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline triglycerides serum levels at 12 and 24 weeks (mg/dl) |
| Secondary | change from baseline C-terminal telopeptide of type 1 collagen at 12 and 24 weeks (ng/dl) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline C-terminal telopeptide of type 1 collagen at 12 and 24 weeks (ng/dl) |
| Secondary | change from baseline Osteocalcin at 12 and 24 weeks (ng/mL) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline Osteocalcin at 12 and 24 weeks (ng/mL) |
| Secondary | change from baseline Bone alkaline phosphatase at 12 and 24 weeks (µg/L) | baseline and then repeated at 12 weeks and 24 weeks | change from baseline Bone alkaline phosphatase at 12 and 24 weeks (µg/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03053115/registered